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Abstract
Particle engineering strategies remain at the forefront of aerosol research for localized treatment of 
lung diseases and represent an alternative for systemic drug therapy. With the hastily growing 
popularity and complexity of inhalation therapy, there is a rising demand for tailor-made inhalable 
drug particles capable of affording the most proficient delivery to the lungs and the most 
advantageous therapeutic outcomes. To address this formulation demand, nanoparticle 
agglomeration was used to develop aerosols of the asthma therapeutics, fluticasone or albuterol. In 
addition, a combination aerosol was formed by drying agglomerates of fluticasone nanoparticles in 
the presence of albuterol in solution. Powders of the single drug nanoparticle agglomerates or of 
the combined therapeutics possessed desirable aerodynamic properties for inhalation. Powders 
were efficiently aerosolized (~75% deposition determined by cascade impaction) with high fine 
particle fraction and rapid dissolution. Nanoparticle agglomeration offers a unique approach to 
obtain high performance aerosols from combinations of asthma therapeutics.
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1. Introduction
Asthma and chronic obstructive pulmonary disease (COPD) are currently treated using 
either nebulizers, pressurized metered dose inhalers or dry powder inhalers (Dalby and 
Suman, 2003; Murnane et al., 2008b; Yang et al., 2008a). A major determinant of aerosol 
deposition in the respiratory tract is the aerodynamic size of particles and the polydispersity 
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(Louey et al., 2004; Pilcer and Amighi, 2010; Pritchard, 2001). Inhaled drugs should ideally 
possess an aerodynamic diameter less than 5 µm for delivery into the ‘deep’ lung for local 
therapy or systemic absorption (Weers et al., 2010). Nanoparticles (<0.5 µm) are more likely 
to be exhaled, which may lead to dose variability (Shi et al., 2007). If delivered as a 
suspension, such small particles are also prone to particle growth due to Ostwald ripening 
and can suffer from uncontrolled agglomeration (Berkland, 2010). A major obstacle to 
inhaled therapeutics is the inability to efficiently deliver large quantities of a drug to the 
deep lung (Gillian, 2010).
Natural aerosols, in particular, spores from molds and fungi as well as soot and asbestos, 
have a size and structure that allows them to aerosolize efficiently into the lungs. They are 
composed of underlying nanostructures that join together to form microparticles. Following 
this rationale, nanoparticle agglomerates were designed by formulating nanometer-sized 
drug particles, then assembling them to micron-sized clusters with the desired aerodynamic 
diameter (e.g., 1 µm for treating distal airways or 3–5 µ m for treating upper airways) 
(Bailey et al., 2008; El Gendy et al., 2009; Plumley et al., 2009). By agglomerating 
nanoparticles under controlled process conditions, nanoparticle agglomerate dry powders 
can be tailored to the desired physical and chemical characteristics for aerosol delivery and 
dissolution (Aillon et al., 2010; El-Gendy and Berkland, 2009).
Asthma is a disease that is commonly treated with two types of aerosolized agents; 
bronchodilators (β2 agonists) and anti-inflammatory agents (steroidal compounds). Apart 
from acute asthma attacks, which are primarily treated with short acting β2 agonists, there is 
a strong need for chronic therapy to reduce inflammation and to avoid asthma exacerbations 
(Barnes, 2002). Therapeutic interventions using combinations of a β2 agonist and a 
glucocorticoid have emerged as an effective asthma management strategy to control 
persistent asthma (Rajeswari et al., 2006). The use of β2 agonists to prevent bronchial spasm 
and glucocorticoids to decrease inflammation is widely accepted (Westmeier and Steckel, 
2008). Combination formulations have also been suggested to be more effective than a 
single drug due to synergistic effects in the same target cell in the lung epithelia. It appears 
rational, therefore, to combine both substances in one particle instead of formulating a 
combination product containing both drugs in a physical mixture (Adi et al., 2008; Nelson et 
al., 2003; Papi et al., 2007).
Combination products such as Advair and Symbicort are currently marketed. Advair 
combines fluticasone propionate and salmeterol xinafoate into one inhaler (Michael et al., 
2000). Salmeterol (long acting β2 agonists) does not replace the need for rescue inhalers, 
such as albuterol, which are still necessary for immediate relief of asthma symptoms (Kamin 
et al., 2007; Salpeter et al., 2006). Symbicort is another combination product containing 
budesonide and formoterol. Fluticasone propionate is a synthetic corticosteroid used to treat 
asthma, allergic rhinitis (hay fever) and eosinophilic esophagitis (Murnane et al., 2008a; 
Rehman et al., 2004; Vatanara et al., 2009). Albuterol sulfate is a short-acting β2 
adrenoreceptor agonist used for the relief of bronchospasm in conditions such as asthma and 
COPD, and is currently one of the most prescribed bronchodilators for the treatment of 
bronchial asthma (Ahmad et al., 2009; Xu et al., 2010).
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Development of dry powder aerosols for delivering fluticasone and/or albuterol nanoparticle 
agglomerates as single anti-asthmatic therapies or in combination to achieve synergistic 
effect is herein described. The study illustrates the formulation of fluticasone nanoparticles 
using potentially acceptable surfactants that control the size and surface charge of the 
prepared nanoparticles. Also, albuterol nanoparticles free of excipients were engineered 
using different techniques. The nanoparticle suspensions were destabilized via ionic charge 
interactions using L-leucine. Combination drug formulations were prepared by adding 
albuterol aqueous solution to the fluticasone nanoparticle suspension followed by addition of 
L-leucine. The aerosol performance of these nanoparticles agglomerate formulations were 
fully characterized and compared to micronized stock drug.
2. Materials and methods
2.1. Materials
Fluticasone propionate (Flu) and albuterol sulfate (Albu) were generously provided by 3M. 
L-α-phosphatidylcholine (lecithin; Lec), cetyl alcohol (CA), L-leucine (Leu) and 
polyvinylpyrrolidone K90 (PVP) were purchased from Sigma Chemical Co., USA. Pluronic 
F-127 (PL, Mw ~12,220) was purchased from BASF, USA. Ethanol, acetone, potassium 
dihydrogen phosphate (KH2PO4), disodium hydrogen phosphate (Na2HPO4) and sodium 
chloride (NaCl) were purchased through Fisher Scientific, USA. Floatable dialysis 
membrane units (MWCO=10 kDa) were obtained from Spectrum Laboratories Inc., USA. 
Amicon Ultra Centrifugal filter units (MWCO=5 kDa) used for dissolution were purchased 
from Millipore, Co (Billerica, MA). Double-distilled water was used throughout the study, 
provided by an EASYpure® RODI (Barnstead International, USA).
2.2. Nanoparticle formulation
2.2.1. Preparation of fluticasone nanoparticle suspension—Nanoparticle 
suspensions of fluticasone propionate were prepared using antisolvent precipitation. 
Solutions of the drug in organic solvent (acetone or ethanol) were prepared at different 
concentrations and directly injected into water at a rate of 2.5 mL/min. A variety of solvent/ 
non-solvent ratios were precipitated under ultrasonication (probe-type sonicator, Fisher 
Scientific, Sonic Dismembrator) operating with an amplitude of 48% in an ice bath or under 
homogenization (probe-type homogenizer, Tissue tearor, Biospec Products, Inc.). 
Hydrophobic surfactants (cetyl alcohol and lecithin) were added to the drug solution while 
hydrophilic surfactants (PL F127, PVA and PVP K90) were dissolved in the aqueous phase.
2.2.2. Formulation of combination therapy—The combined formulation was prepared 
by adding albuterol sulfate dissolved in water to the precipitated fluticasone propionate 
nanosuspension during homogenization at 25,000 rpm. The two drugs were combined, at a 
ratio of 2:1 w/w, fluticasone propionate: albuterol sulfate (Papi et al., 2007; Westmeier and 
Steckel, 2008).
2.2.3. Fabrication of albuterol nanoparticle suspension—Albuterol sulfate 
nanoparticles were prepared by precipitation or by a top-down (attrition) method. 
Concerning the precipitation technique, solutions of albuterol in water were prepared and 
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directly injected into ethanol or acetone at a rate of 2.5 mL/min. Various solvent/ non-
solvent ratios were used under ultrasonication operating with an amplitude of 48% or under 
homogenization. In the top-down method, albuterol nanoparticles were prepared by 
ultrasonicating or homogenizing a suspension of albuterol in acetone or ethanol. The 
concentration of the drug in the anti-solvent was varied between 0.2 and 1 mg/mL. The 
ultrasonication or homogenization time was also varied.
2.3. Characterization of nanoparticle suspensions
The average size and polydispersities of the nanoparticle suspensions were determined by 
dynamic light scattering (Brookhaven, ZetaPALS, SA). The same instrument was used to 
determine the zeta potential of the nanoparticles in 1 mM potassium chloride solution. Three 
runs of 15 cycles were acquired, and the mean zeta potential was recorded. Measurements 
were taken at an angle of 90° to the incident light source. Some samples were frozen at −80 
°C and lyophilized (FreeZone 1) for ~36 h at a temperature of −50 °C under vacuum (~0.02 
millibar). Lyophilized powder was stored at room temperature for further characterization.
2.4. Agglomeration of nanoparticle suspensions
Nanoparticles were agglomerated via addition of an agglomerating agent. L-Leucine solution 
in water (2.5 mg/mL) was slowly injected into nanoparticle colloids during homogenization 
at 25,000 rpm for 30 s. The amount of L-leucine added was adjusted to a fluticasone: L-
leucine ratio equal to 1:1 for agglomerating the fluticasone suspension and the combination 
suspension. An albuterol: L-leucine ratio of 1:1.5 was used for agglomerating the albuterol 
suspension.
The agglomerated suspensions were incubated with the agglomerating agent for three hours. 
Then, the size of the prepared nanoparticle agglomerates was measured in Isoton diluent 
using a Coulter Multisizer 3 (Beckman Coulter Inc.) equipped with a 100 µm aperture. The 
suspensions were kept overnight at room temperature to allow evaporation of organic 
solvent and then frozen at −80 °C. The frozen suspensions were transferred to the freeze 
dryer where drying lasted for ~3 days. Lyophilized powder was stored at room temperature 
for further characterization.
2.5. Particle size and morphology by transmission electron microscopy (TEM)
Lyophilized powders were resuspended in Isotonic solution and the particle size and size 
distribution was detected using a Coulter Multisizer 3. In addition, the size and morphology 
of the lyophilized nanoparticles and nanoparticle agglomerate powders were evaluated using 
JEOL 1200 EXII transmission electron microscope. Prior to imaging, carbon-coated grids 
(Electron Microscopy Sciences) were placed on a droplet of the suspensions on a glass 
microscope slide to permit the adsorption of the particles onto the grid. After this, the grid 
was blotted with a filter paper and air dried for 1 h.
2.6. Powder flow characteristics
Nanoparticle agglomerate dry powders were poured through a glass funnel from a height of 
4 cm onto a level bench top. The angle that the side of the conical heap made with the 
horizontal plane was recorded as the angle of repose (tan θ = height / radius). In addition, 
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bulk and tapped densities were determined. Then, the Hausner ratio (tapped density / bulk 
density) and Carr’s compressibility index (Ci) [(tapped density – bulk density)/ tapped 
density X 100%] were calculated (Kumar et al., 2001; Louey et al., 2004).
2.7. Evaluation of Aerosol performance of nanoparticle agglomerate dry powders
2.7.1. Measurement of theoretical mass mean aerodynamic diameter—The 
geometric particle size and tap density measurements were used for calculating the 
theoretical mass mean aerodynamic diameter (dae) of the nanoparticle agglomerates (El-
Gendy et al., 2010b; Fiegel et al., 2008).
2.7.2. Aerodynamic size distribution by time-of-flight analysis—The aerodynamic 
diameter and size distributions of the nanoparticle agglomerate powders were determined by 
time-of-flight measurement (TOF) using an Aerosizer LD (Amherst Instruments, Hadely, 
MA, USA) equipped with a 700 µm aperture operating at 6 psi. For these studies, ~1 mg of 
the powder was added to the instrument disperser and data were collected for ~60 s under 
high shear force (~3.4 kPa). The instrument size limits were 0.10–200 µm and particle 
counts were above 100,000 for all measurements.
2.7.3. In vitro aerosol deposition of nanoparticle agglomerates by cascade 
impactor—An eight-stage Mark II Andersen Cascade Impactor (ACI, Tisch 
Environmental, Inc.) had stages with particle aerodynamic diameter specifications at a flow 
rate of 28.3 L/min as follows: pre-separator (10.00 µm), stage 0 (9.00 µm), stage 1 (5.80 
µm), stage 2 (4.70 µm), stage 3 (3.30 µm), stage 4 (2.10 µm), stage 5 (1.10 µm), stage 6 
(0.70 µm), stage 7 (0.40 µm) and the final filter (< 0.40 µm). Aerodynamic behavior of 
nanoparticle agglomerate dry powders was assessed using the ACI and compared with that 
of the two drugs as received.
The powder was delivered into the cascade impactor by placing capsules (gelatin type, size 
3, generously provided from Capsugel®, NJ, USA) containing 5 ± 0.5 mg of powder into a 
Plastiape Monodose Inhaler RS01 Model 7. The capsule was punctured and the powder was 
drawn through the cascade impactor which was operated at a flow rate of 28.3 L/min for 4 s. 
Dry powder aerosols deposited on each of the nine stages of the impactor were quantified by 
HPLC. After actuation, the device, capsule, adapter, throat, all plates, stages and filter were 
washed into separate volumetric flasks using ethanol (for fluticasone alone or Flu/Alu 
combination) or phosphate buffered saline (pH 7.4 for albuterol). Appropriate sample 
dilutions were made prior to testing by HPLC. Each sample was tested in triplicate.
Concerning the combination formula, the powder deposited on stages was suspended in 
ethanol and was ultrasonicated in a bath-type sonicator (Branson 3510) for 30 min. Then, 
the solution was centrifuged (Beckman, Avanti ) at ~15,000 rpm for 30 min and the amount 
of fluticasone in the supernatant was determined using a reversed-phase HPLC method. As 
albuterol has a very slightly solubility in ethanol, the drug content in both supernatant and 
precipitate were detected by HPLC.
All ACI experiments were performed under controlled conditions (21 ± 2 °C, 50 ± 5% RH) 
in triplicate. The emitted dose (ED) was defined as the mass of drug delivered from the 
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inhaler (i.e., total amount excluding the inhaler device and capsule) (Xu et al., 2010). The 
emitted fraction was determined as the percent of the emitted dose divided by the initial 
mass delivered into the impactor (Lechuga-Ballesteros et al., 2008; Shur et al., 2008; Yang 
et al., 2008b).
The fine particle fraction of the total dose (FPFTD) was calculated as the percentage of 
aerosolized particles that reached the lower seven stages of the impactor (corresponding to 
aerodynamic diameters below 5 µm; stage 2-filter), or the lower five stages (corresponding 
to aerodynamic diameters below 3 µm; stage 4-filter) (El-Gendy et al., 2010a).
The fine particle fraction of the emitted dose (FPFED) was determined from the cumulative 
mass distribution curve at 5 µm and 3 µm and was calculated as a function of the emitted 
dose. Additionally, mass median aerodynamic diameter (MMAD) and geometric standard 
deviation (GSD) were determined from the cumulative mass distribution curve (Pham and 
Wiedmann, 2001; Vanbever et al., 1999; Xu et al., 2010).
2.8. Solid-state characterization
2.8.1. Power X-Ray Diffraction (PXRD)—For analysis of crystallinity, X-ray diffraction 
analysis was performed using an XGEN-4000 (Scintag, Inc.). The powders were analyzed 
over the range of 5° to 45° (2θ) at 45.0 kV and 35.0 mA.
2.8.2. Differential scanning calorimetry (DSC)—DSC data of materials as received, 
nanoparticles and nanoparticle agglomerates were collected using a Q100 DSC from TA 
Instruments. For thermogram acquisition, sample sizes of 1 to 5 mg were weighed into 
aluminum hermetic pans. Measurement was carried out under inert conditions (nitrogen 
flow of 50 mL/min) with a scan rate of 10 °C/min from 25 to 350 °C.
2.8.3. Thermogravimetric analysis (TGA)—TGA was also performed using a Q50 
TGA from TA Instruments. A platinum sample pan was loaded with 5 ± 0.5 mg of sample 
and heated from 25 to 350 °C at a rate of 10 °C/min under dry nitrogen flowing at rate of 40 
mL/min. Data analysis was completed using Universal Analysis 2000 (Version 4.3A) 
software that was provided by TA Instruments.
2.9. Determination of process yield
The weight of dry powder for the prepared nanoparticle agglomerates was measured and the 
yield was calculated (El Gendy et al., 2009).
2.10. Determination of drug content uniformity of nanoparticle agglomerates
Fluticasone content in the dry powders was assessed by dispersing 1 mg of the lyophilized 
powder in 10 mL of ethanol. The dispersion was ultrasonicated in a bath-type sonicator for 
30 min. Then the solution was centrifuged at ~15,000 rpm for 30 min to remove insoluble 
ingredients and the amount of fluticasone in the supernatant was determined using a 
reversed-phase HPLC method. For the combination formula, albuterol content was detected 
in both the pellet after dissolving in 10 mL PBS and in the supernatant using HPLC. Drug 
content in albuterol nanoparticle agglomerates was determined by dispersing 1 mg of the 
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lyophilized powder in PBS. The dispersion was ultrasonicated in a bath-type sonicator for 
15 min. Then the amount of albuterol was determined using a reversed-phase HPLC method. 
All experiments were performed in triplicate and drug content was calculated (El Gendy et 
al., 2009).
2.11. Dissolution studies
The dissolution of the prepared nanoparticles and nanoparticle agglomerates was determined 
under sink condition and compared with the dissolution of the drugs as received. The 
dissolution of fluticasone was carried out at 37 ± 0.5 °C in a 1 liter beaker. Lyophilized 
powder (~10 mg) was dispersed in 10 mL PBS (pH 7.4) and was suspended in a floatable 
dialysis membrane unit (Mw cut-off = 10 kDa). The unit was allowed to float in 500 mL of 
PBS and the whole assembly was stirred at a constant speed (100 rpm) using a magnetic 
stirrer (Barnstead, Thermolyne MIRAK™). At predetermined time intervals for a total 
period of 8 h, samples (1 mL) of the medium were withdrawn from the dialysis bag and 
replaced with fresh medium. Then, the samples were centrifuged for 30 min at ~13,000 rpm. 
The supernatant was removed and the pellet was dissolved in 1 mL of ethanol. Fluticasone 
content was determined using reversed-phase HPLC. In the case of the combination 
formula, both pellet and supernatant were analyzed for albuterol using a reversed-phase 
HPLC method. Studies were conducted in triplicate.
For albuterol dry powders, 5 mg was dispersed in 0.6 mL phosphate buffered saline (PBS, 
pH 7.4) and placed in a 5 kDa Ultra Centrifugal filter unit which was immersed inside a 10 
mL centrifugal tube containing PBS solution to a final volume of 7 mL. All samples were 
incubated at 37 ± 0.5 °C and shaken at 100 rpm. One mL aliquots were taken at various time 
points up to 8 hours from the bulk solution and replaced with 1 mL of fresh PBS. The drug 
concentration was measured using reversed-phase HPLC. All experiments were performed 
in triplicate.
2.12. Quantitative analysis of the drug concentrations by HPLC
Drug content, dissolution, and ACI concentration on stages were carried out using reversed-
phase HPLC methods. A Shimadzu HPLC system including a solvent delivery pump 
(Shimadzu LC-10AT), a controller (Shimadzu SCL-10A), SIL-10AxL autoinjector, and a 
SPD-10A UV detector was used in this study. Chromatograms were acquired and analyzed 
using Shimadzu Class VP 4.3 software. A long Zorbax SB C-18 column (Agilent C; 4.6 mm 
× 100 mm) with a particle diameter of 3.5 µm was used for separation. During the assay of 
fluticasone, the drug was eluted isocratically at a mobile phase flow rate of 1.2 mL/min and 
monitored with a UV detector operating at 238 nm. The mobile phase for the assay consisted 
of an acetonitrile and water mixture (65:35 v/v) (Asmus et al., 2004; Steckel and Muller, 
1998). The run time for the assay was 10 minutes, and the retention time for fluticasone was 
3.9 ± 0.2 min. For analyzing albuterol samples, an isocratic system was used with mobile 
phase of 90:10 v/v phosphate buffer (10 mM, pH3.5): acetonitrile at a flow rate of 0.3 
mL/min and detection was performed at 225 nm (Kamin et al., 2007). The run time for the 
assay was 10 min, and the retention time for albuterol was 3.85 ± 0.4 min.
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3. Results and discussion
3.1. Fluticasone nanopaticle suspensions made by precipitation
To obtain small nanoparticles from poorly water soluble fluticasone propionate, a non-
solvent precipitation method was employed (Bilati et al., 2005). Selected surfactants were 
chosen from a list of excipients that may be appropriate for inhalation (Chougule et al., 
2007; Pilcer and Amighi, 2010). Different suspensions were produced using water as anti-
solvent and a drug concentration of 0.1% or 0.2% w/w dissolved in ethanol or acetone. 
Fluticasone particles prepared without surfactants were very large with high polydispersity. 
Mean diameters of fluticasone nanoparticles made with individual surfactants were larger 
than those with combined surfactants. Particle size tended to increase and colloidal stability 
was difficult to maintain as fluticasone concentration was increased. Nanoparticles 
precipitated from acetone were larger than those precipitated from ethanol. Nanoparticle size 
appeared to decease slightly when using ultrasonication rather than homogenization during 
the precipitation process (Supplementary Table 1).
The most successful fluticasone nanosuspension was prepared by precipitation from ethanol 
under ultrasonication (0.1% w/v Flu + 0.01% w/v PVP + 0.005% w/v Lec). The surfactant 
combination employed yielded a small drug particle size (~400 nm) and low polydispersity 
(0.132). The charged surface of the nanoparticles (~12 mV) allowed the potential to 
destabilize this colloid via interaction with an agglomerating agent (Table 1). This formula 
was chosen for the preparation of the fluticasone nanoparticle agglomerates and for the 
combination formulation with albuterol sulfate in solution.
3.2. Albuterol nanoparticle suspensions made by two approaches
3.2.1. Production of nanoparticles by precipitation—Albuterol nanoparticles were 
first prepared by precipitation. A smaller nanoparticle size was produced when using 
acetone as non-solvent as opposed to ethanol. A decrease in particle diameter followed from 
a decrease of the drug concentration. The smallest nanoparticle size was obtained at a 2.5/25 
water/acetone ratio at a drug concentration of 0.1 % w/v; however, the polydispersity was 
high with low yields for all precipitation trials (Supplementary Table 2).
3.2.2. Production of nanoparticles by attrition—Nanoparticles were also produced 
by fragmenting micronized drug particles using homogenization or ultrasonication. The 
homogenizer was superior to ultrasonication in the preparation of albuterol nanoparticles 
causing a significant decrease in size with low polydispersity (Supplementary Table 3). With 
these considerations in mind, the A7 nanoparticle formulation was selected which was 
prepared by homogenizing a suspension of the drug in acetone in a concentration of 1 
mg/mL for 15 min (Table 1).
3.3. Agglomeration of the formulated nanoparticles
Colloidal suspensions of fluticasone nanoparticles, albuterol nanoparticles (A7) and 
fluticasone nanoparticles combined with albuterol in solution were destabilized using L-
leucine to disrupt the electrostatic repulsion between particles (Young et al., 2002). The 
resulting nanoparticle agglomerates had a geometric size of ~3–5 µm (Table 2). After 
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drying, powders showed a slightly broader size distribution (Fig. 1). In addition, the 
combination powders had a wider distribution compared to the single-drug formulations, 
perhaps due to large albuterol particles formed during freeze drying.
The particle size of the nanoparticles and nanoparticle agglomerates was congruent with the 
structures observed in TEM micrographs. Fluticasone nanoparticles were slightly elongated 
with smooth surfaces and a particle size of ~400 nm (Fig. 2A). Nanoparticle agglomerates 
appeared as elongated nanoparticles that were agglomerated together into micron-sized 
clusters with a somewhat porous structure (Fig. 2B). The combination powders of 
fluticasone nanoparticles dried with albuterol in solution generally exhibited slightly larger 
particles with a rough surface. Presumably, albuterol in solution deposited on the rod-shaped 
fluticasone particles during drying (Fig. 2C). Small albuterol nanoparticles with a particle 
diameter less than 100 nm were (Fig. 3A) [/agglomerated into micron-sized particles (Fig. 
3B).
Powder properties for micronized drugs as received and nanoparticle agglomerates were also 
studied. Flowability and density characterization helped elucidate any differences in bulk 
powder properties (Table 3). Flowability indices were calculated from density differences 
and the angle of repose. The micronized drugs showed a larger angle of repose, greater tap 
density and higher values of the Hausner ratio and Carr’s index compared to the 
nanoparticle agglomerates (Fig. 4). This was probably the result of a reduction of cohesive 
forces in nanoparticle agglomerates compared to drug powders as received. L-Leucine may 
have also reduced surface energy in nanoparticle agglomerate dry powders (Shur et al., 
2008).
3.4. Nanoparticle agglomerates yielded desirable aerosol characteristics
Theoretical mass mean aerodynamic diameters (daero) of the prepared nanoparticle 
agglomerates were calculated from the geometric particle size and tap density. The 
calculated daero (0.8–1.1 µm) was appropriate for increasing the probability of aerosol 
deposition in the alveolar region of the lungs. Aerosizer LD time-of-fight (TOF) 
measurements of nanoparticle agglomerate dry powders also showed particles in the 
respirable size range (2 – 3.2 µm) with relatively narrow size distribution (Table 2 and Fig. 
5). The MAD value of the combination formula obtained by Aerosizer appeared to be close 
to that of the pure fluticasone nanoparticle agglomerates.
Cascade impactor analysis is the standard technique for in vitro characterization of dry 
powder aerosols. Fluticasone nanoparticle agglomerates mainly deposited on stages 3 and 4, 
while albuterol nanoparticle agglomerates favored deposition on stages 4 and 5 of the 
impactor. The combination formula exhibited size distribution similar to fluticasone 
nanoparticle agglomerates with some additional powder deposition on upper stages. This 
may be explained by the fact that once fluticasone nanoparticle agglomerates were dried in 
the presence of albuterol in solution, forces such as van Der Waals are sufficient to hold all 
particles together. This may suggest that fluticasone nanoparticle agglomerates were indeed 
a ‘carrier’ for much of the albuterol. Albuterol in the combination showed a different 
deposition profile than the fluticasone, although the albuterol deposition was improved 
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compared to the albuterol as received. This may be due to the segregation of some larger 
albuterol particles from the fluticasone nanoparticle agglomerates.
Conversely, drug powders as received largely deposited on the mouthpiece, throat and the 
upper stages (Fig. 6). A larger percentage of fluticasone (27%) and albuterol (28%) powder 
as received remained in the capsule shell and device when compared to the nanoparticle 
agglomerates (9% for Flu NA, 11% for Albu NA and 18% for the combined formulation). 
This reflected the efficient aerosolization and high fine particle fraction of the nanoparticle 
agglomerates. In addition, the irregular shape of the nanoparticle agglomerates may decrease 
their contact area with device surfaces, thus resulting in superior dispersion properties.
The aerosol performance was described according to emitted fraction (EF), emitted dose 
(ED), fine particle fraction (FPF), and mass median aerodynamic diameter (MMAD) (Table 
4). The high EF (~75–90%) and ED of nanoparticle agglomerate dry powders obtained at 
the tested flow rate suggested efficient aerosolization of the nanoparticle agglomerates as 
compared to the micronized drugs as received. All prepared formulas offered high fine 
particle fraction with anticipated total lung deposition (FPFTD <5 µm) of about 74–88% and 
deep lung deposition (FPFTD<3 µm) of ~55–62%. No significant change in FPF of 
fluticasone was observed after combination with albuterol in solution, suggesting the 
fluticasone nanoparticle agglomerates were indeed a carrier for albuterol (Table 4). Analysis 
of the drug content on each stage indicated that some larger albuterol particles were 
segregated from the fluticasone nanoparticle agglomerates (Fig. 7). The drug powders as 
received gave significantly lower FPF compared to all prepared nanoparticle agglomerates.
The mass median aerodynamic diameter (MMAD) was calculated from ACI data as the 50th 
percentile of the aerodynamic particle size distribution by mass. MMADs of the nanoparticle 
agglomerates ranged from 2–3.5 µm (Table 4). These values were very close to the 
Aerosizer data but slightly higher than the theoretical MMAD calculations as expected. In 
addition, the geometric standard deviation (GSD) was determined (El-Gendy et al., 2010a; 
Xu et al., 2010). GSDs for the selected nanoparticle agglomerates ranged between 2.1 and 
2.5, suggesting an acceptable range of particle size (Table 4).
Nanoparticle agglomerate formulations reported here offered a highly efficient aerosol in 
comparison to previous reports. For example, Steckel et al. prepared fluticasone by milling 
and micronization and evaluated the powder using a multi-stage liquid impinger. The 
highest fine particle fraction (% FPF <5µm) was achieved when using a FlowCaps® inhaler 
without lactose (37.5 %) (Steckel et al., 2003). Louey et al. explored multiple methods to 
generate fluticasone particles and characterized the aerosol using an eight-stage cascade 
impactor with pre-separator. Low-resistance (Rotahaler) and high-resistance (Inhalator) 
inhalers were compared. The Inhalator yielded the highest FPF (11.95%) for the jet milled 
powder blended with lactose (Louey et al., 2004). Very fine aerosols of albuterol are more 
common in the literature. For example, Chiou et al. and Hu et al. formulated salbutamol 
sulfate using high gravity controlled precipitation and assessed these powders using an 
Aerolizer connected to a multi-stage liquid impinger. They achieved similar albuterol 
performance as was reported here, the best reported FPFloaded and FPFemitted was 76.5% and 
83.7%, respectively (Chiou et al., 2007; Hu et al., 2008). Aerosol performance of fluticasone 
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in combination with salmeterol seemed to revert more towards the values reported for 
fluticasone. Westmeier et al. formulated these actives together by precipitation in a 
micromixer. The aerodynamic behavior of the particles was assessed using a Next 
Generation Impactor. Even though a high flow rate of 100 L/min was used, an Aerolizer 
device still only produced a FPF of 36.4% when the actives were blended with lactose 
(Westmeier and Steckel, 2008).
3.5. Crystallinity and thermal properties
PXRD was performed to analyze the nanoparticles and nanoparticle agglomerates. The X-
ray diffraction patterns showed sharp diffraction peaks suggesting that both fluticasone as 
received and nanoparticles were crystalline (Fig. 8) (Louey et al., 2004; Murnane et al., 
2008a; Yang et al., 2008a). The pattern of fluticasone nanoparticle agglomerates showed 
features of L-leucine and fluticasone nanoparticles. There was a peak at ~7.5° in the pattern 
of the drug as received that did not appear in that of the nanoparticles or nanoparticle 
agglomerates. On the other hand, a peak at 9° was apparent in the patterns of fluticasone 
nanoparticles and nanoparticle agglomerates, perhaps due to a slight change in the crystal 
arrangement (Fig. 8). Nanoparticle agglomerates also had diffraction peaks at 12° and 27.5° 
that differed from the nanoparticle pattern, which suggested some overlap with L-leucine 
peaks. The intensity of the diffraction peaks of the nanoparticles and nanoparticle 
agglomerates was low due to the small particle size. The PXRD pattern of combination 
nanoparticle agglomerates illustrated the features of L-leucine, fluticasone nanoparticles and 
albuterol as received (Fig. 9). The results indicated that fluticasone in this formulation 
showed the same crystalline form of fluticasone as received.
Both albuterol as received and albuterol nanoparticles showed crystalline character (Fig. 10) 
(Xu et al., 2010). The X-ray diffraction pattern of albuterol nanoparticles was different from 
that of albuterol as received as a result of the appearance of a peak at ~10° in the 
nanoparticle sample. This peak disappeared after agglomeration. The albuterol nanoparticle 
agglomerate pattern had features of L-leucine and albuterol as received indicating that the 
crystal form of nanoparticle agglomerates was likely the same crystal form as that of 
albuterol as received (Fig. 10).
Fluticasone and albuterol nanoparticles and nanoparticle agglomerates were also analyzed 
using differential scanning calorimetry (Table 5 and Fig. 11–13). No characteristic melting 
peak was found in fluticasone as received or the prepared nanoparticles. Micronized 
fluticasone as received showed an endothermic degradation peak at 282.51 °C while the 
selected nanoparticles exhibited an exothermic degradation peak at 278.42 °C (Louey et al., 
2004; Westmeier and Steckel, 2008). For lecithin, there was a sharp melting endotherm at 
168.2 °C. A DSC scan of PVP K90 showed a shallow, broad endothermic peak at 75.29 °C 
with an enthalpy of −0.835 W/g. L-Leucine powders sublimed at 323.7 °C. The DSC curve 
of fluticasone nanoparticle agglomerates exhibited an endothermic peak of melting at 210.17 
°C with an enthalpy change of −2.447 W/g followed by subsequent degradation of the 
compound; however, the characteristic peaks of the excipients were not apparent (Fig. 11A). 
This may be indicative of some re-crystallization of the drug during the agglomeration 
process or some overlap of excipient peaks.
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Combination nanoparticle agglomerates included fluticasone NP with albuterol in solution 
and L-leucine having been freeze dried from solution. The DSC thermogram exhibited an 
endothermic peak at 228.65 °C, Fig. 11B. This may be a result of some overlap of albuterol 
and excipient peaks. This peak was also similar to that of fluticasone nanoparticle 
agglomerates with a slight shift that may be indicative of the same crystalline form in both 
single and combination fluticasone nanoparticle agglomerate formulations.
The DSC data of albuterol as received showed an endothermic peak at 206.49 °C with an 
enthalpy change of −2.209 W/g followed by subsequent degradation of the compound (Fig 
11C). It has been reported that this degradation could be explained by a possible dehydration 
of the alcoholic function (catalyzed by sulfuric acid present in the molecule) and then 
oxidation (Hadef et al., 2008; Raula et al., 2008; Xu et al., 2010). The DSC scans for both 
the drug as received and nanoparticles of albuterol were similar with no change in the 
melting points (Table 5). This indicated that creating nanoparticles by attrition may not 
affect the physical characteristics of albuterol. The sharpness of the peak seen in the 
nanoparticle formulation also suggested crystallinity. Albuterol in the nanoparticle 
agglomerates showed a shifted endothermic event that appeared at 259.22 °C with an 
enthalpy of −3.126 W/g. This may have resulted from some overlap with the sublimation 
peak of L-leucine that is usually observed at 323.7 °C (Raula et al., 2008). 
Thermogravimetric studies also support these findings (Supplementary Fig. 1 and 
Supplementary Text)
3.6. Fluticasone and albuterol nanoparticle agglomerate dissolution
All nanoparticle agglomerates were produced with a high yield (~86–96 %) and with low 
batch variation (Table 6). All prepared nanoparticle agglomerates exhibited high drug 
content which ranged from 82% to 92% (Table 6), indicating negligible loss of drug during 
formation. The cumulative percentage of fluticasone dissolved from nanoparticle 
agglomerates after 8 h (Q8h) was found to be slower than that of the nanoparticles and faster 
than that of the drug as received (Table 6 and Fig. 12A). This was the expected result of 
increasing the surface area by decreasing the particle size. There was no significant 
difference in the fluticasone dissolution from the combination nanoparticle agglomerates 
and nanoparticle agglomerates containing only fluticasone. There was a slight delay in the 
dissolution of albuterol from nanoparticle agglomerates in the first 90 min followed by 
dissolution behavior similar to that of the micronized drug as received. On the other hand, 
no significant difference was observed in the dissolution performance of albuterol from 
nanoparticles, drug as received and combination therapy over 8 h (Fig. 12B). These results 
were likely due to high solubility of albuterol. Fluticasone nanoparticles did not affect the 
dissolution of albuterol in the combination formula.
4. Conclusion
Inhaled dry powders represent a preferred formulation for first-line therapy treating asthma 
and chronic obstructive pulmonary diseases. Combination powders may provide 
simultaneous delivery to the same site of action increasing the potential synergistic effect of 
the drugs. A challenging task in engineering dry powders is achieving the aerosol particle 
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size that can avoid the physiological barriers of the lung and deliver the drug to the 
appropriate lung region. Here, fluticasone and albuterol were fabricated into nanoparticle 
suspensions. Agglomeration of these suspensions produced micrometer-sized nanoparticle 
agglomerate aerosols with a large fine particle fraction (particles ~1–5 µm in diameter) and 
nanostructure for improving the dissolution rate of poorly water soluble fluticasone. The 
powders reported here offer a novel formulation for localizing potent drugs as single agents 
or in combination for the treatment of asthma and chronic obstructive pulmonary disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The particle size distributions of A) fluticasone nanoparticle agglomerates, B) Flu/Albu 
combination and C) albuterol nanoparticle agglomerates in suspension after agglomeration 
and resuspended after lyophilization.
El-Gendy et al. Page 18














Transmission electron micrographs of A) fluticasone nanoparticles B) fluticasone 
nanoparticle agglomerates and C) Flu/Albu combination.
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Transmission electron micrographs of albuterol sulfate A) nanoparticles and B) nanoparticle 
agglomerates.
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Comparison in the density for the same mass between A) fluticasone powder as received, B) 
fluticasone nanoparticle agglomerates, C) Flu/Albu combination, D) albuterol nanoparticle 
agglomerates and E) albuterol powder as received.
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Aerodynamic size distributions of A) fluticasone nanoparticle agglomerates, B) Flut/Albu 
combination and C) albuterol nanoparticle agglomerates after lyophilization determined by 
time-of-flight analysis.
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The distribution of fluticasone nanoparticle agglomerates, Flu/Albu combination and 
albuterol nanoparticle agglomerates deposited on the stages of a cascade impactor at a flow 
rate of 28.3 L/min using a Monodose inhaler and compared to the drugs as received.
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The percent of fluticasone and albuterol in Flu/Albu combination deposited on the stages of 
a cascade impactor at a flow rate of 28.3 L/min using Monodose inhaler.
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Powder X-ray diffraction patterns: (a) L-leucine, (b) fluticasone as received, (c) fluticasone 
nanoparticles, and (d) fluticasone nanoparticle agglomerates.
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Powder X-ray diffraction patterns: (a) L-leucine, (b) fluticasone as received, (c) fluticasone 
nanoparticles, (d) albuterol as received, and (e) Flu/Albu combination.
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Powder X-ray diffraction patterns: (a) L-leucine, (b) albuterol as received, (c) albuterol 
nanoparticles, and (d) albuterol nanoparticle agglomerates.
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Differential scanning calorimetry thermograms for A) fluticasone nanoparticle agglomerates 
(NA), B) Flu/Albu combination and C) albuterol nanoparticle agglomerates (NA).
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Dissolution profiles of A) fluticasone and B) albuterol in PBS (pH 7.4) from drug powder as 
received, nanoparticle formulation (NP), nanoparticle agglomerate formulation (NA) and 
Flu/Albu combination.
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Table 1
Formulation composition and characterization of the selected fluticasone and albuterol nanoparticles (values = 











Nanoparticle size (nm) 403.8 ± 3
Polydispersity 0.3 ± 0.01










Nanoparticle size (nm) 46 ± 2
Polydispersity 0.1 ± 0.04
Zeta-potential (mV) 10 ± 1
a
H = homogenization process at 25,000 rpm
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Table 2









Geometric particle size (µm) of NCe before
lyophilization
3.8 ± 1.1 3.9 ± 1.3 4.1 ± 1.5
Geometric particle size (µm) of lyophilized
NCd
4.8 ± 1.0 5.4 ± 2.0 5 ± 0.9
MADAe of lyophilized NCd 2.1 ± 0.1 3.2 ± 0.1 1.9 ± 0.02
MMADtf of lyophilized NCd 0.98 ± 0.1 1.1 ± 0.01 0.8 ± 0.05
a
Fluticasone NC = 1: 0.05: 0.1: 1; Flu: Lec: PVP K90: Leu
b
Albuterol NC = 1: 1.5; Albu: Leu
c
Flu/Albu combination = 2: 1; Flu: Albu
d
NA = Nanoparticle agglomerates.
e
MADA = Median aerodynamic diameter obtained from Aerosizer.
f
MMADt = Theoretical mass mean aerodynamic diameter calculated from density measurements.
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Table 5





Fluticasone powder as received ------ ------
Fluticasone NPd ------ ------
Fluticasone NAa 210.17 −2.447
Albuterol powder as received 206.49 −2.209
Albuterol NP 206.49 −2.2
Albuterol NA b 259.22 −3.126
Flu/Albu combination c 228.65 −3.273
Lecithin powder as received 168.2 −2.76
PVP K90 powder as received 75.29 −0.835
L-leucine powder as received 323.7 −6.914
a
Fluticasone NA = 1: 0.05: 0.1: 1; Flu: Lec: PVP K90: Leu
b
Albuterol NA = 1: 1.5; Albu: Leu
c
Flu/Albu combination = 2: 1; Flu: Albu
d
NP = Nanoparticles
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Table 6
Yield, content and dissolution behavior of fluticasone and albuterol nanoparticle agglomerates (values = 








Process yield of lyophilized
NA (%) 86 ± 7 96 ± 2 90 ± 3
% Drug content of Flu & Albu
in the lyophilized NA 92 ± 5 85.3 ± 7 90 ± 3 82 ± 6
Q8hd NP 96 ± 1 100 ± 0.4 n/a n/a
Q8h NA 75 ± 7 100 ± 8 73 ± 10 100 ± 6
a
Fluticasone NC = 1: 0.05: 0.1: 1; Flu: Lec: PVP K90: Leu
b
Albuterol NC = 1: 1.5; Albu: Leu
c
Flu/Albu combination = 2: 1; Flu: Albu
d
Q8h = % Fluticasone (Flu) and albuterol (Albu) dissolved after 8 hours.
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